199 related articles for article (PubMed ID: 28993206)
1. Targeting receptor tyrosine kinase EphB4 in cancer therapy.
Chen Y; Zhang H; Zhang Y
Semin Cancer Biol; 2019 Jun; 56():37-46. PubMed ID: 28993206
[TBL] [Abstract][Full Text] [Related]
2. Biological Significance of EphB4 Expression in Cancer.
Ullah A; Razzaq A; Zhou C; Ullah N; Shehzadi S; Aziz T; Alfaifi MY; Elbehairi SEI; Iqbal H
Curr Protein Pept Sci; 2024; 25(3):244-255. PubMed ID: 37909437
[TBL] [Abstract][Full Text] [Related]
3. EphB4: A promising target for upper aerodigestive malignancies.
Salgia R; Kulkarni P; Gill PS
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):128-137. PubMed ID: 29369779
[TBL] [Abstract][Full Text] [Related]
4. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.
Martiny-Baron G; Holzer P; Billy E; Schnell C; Brueggen J; Ferretti M; Schmiedeberg N; Wood JM; Furet P; Imbach P
Angiogenesis; 2010 Sep; 13(3):259-67. PubMed ID: 20803239
[TBL] [Abstract][Full Text] [Related]
5. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.
Noren NK; Yang NY; Silldorff M; Mutyala R; Pasquale EB
Biochem J; 2009 Aug; 422(3):433-42. PubMed ID: 19552627
[TBL] [Abstract][Full Text] [Related]
6. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
[TBL] [Abstract][Full Text] [Related]
7. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
Lafleur K; Huang D; Zhou T; Caflisch A; Nevado C
J Med Chem; 2009 Oct; 52(20):6433-46. PubMed ID: 19788238
[TBL] [Abstract][Full Text] [Related]
8. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
Ferguson BD; Liu R; Rolle CE; Tan YH; Krasnoperov V; Kanteti R; Tretiakova MS; Cervantes GM; Hasina R; Hseu RD; Iafrate AJ; Karrison T; Ferguson MK; Husain AN; Faoro L; Vokes EE; Gill PS; Salgia R
PLoS One; 2013; 8(7):e67668. PubMed ID: 23844053
[TBL] [Abstract][Full Text] [Related]
9. EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target.
Xiao Z; Carrasco R; Kinneer K; Sabol D; Jallal B; Coats S; Tice DA
Cancer Biol Ther; 2012 Jun; 13(8):630-7. PubMed ID: 22555806
[TBL] [Abstract][Full Text] [Related]
10. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.
Aslam MI; Abraham J; Mansoor A; Druker BJ; Tyner JW; Keller C
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6383-8. PubMed ID: 24733895
[TBL] [Abstract][Full Text] [Related]
11. EphB4 forward signalling regulates lymphatic valve development.
Zhang G; Brady J; Liang WC; Wu Y; Henkemeyer M; Yan M
Nat Commun; 2015 Apr; 6():6625. PubMed ID: 25865237
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4.
Duggineni S; Mitra S; Noberini R; Han X; Lin N; Xu Y; Tian W; An J; Pasquale EB; Huang Z
Biochem Pharmacol; 2013 Feb; 85(4):507-13. PubMed ID: 23253822
[TBL] [Abstract][Full Text] [Related]
13. Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity.
Chrencik JE; Brooun A; Recht MI; Kraus ML; Koolpe M; Kolatkar AR; Bruce RH; Martiny-Baron G; Widmer H; Pasquale EB; Kuhn P
Structure; 2006 Feb; 14(2):321-30. PubMed ID: 16472751
[TBL] [Abstract][Full Text] [Related]
14. Expression of Ephb2 and Ephb4 in breast carcinoma.
Wu Q; Suo Z; Risberg B; Karlsson MG; Villman K; Nesland JM
Pathol Oncol Res; 2004; 10(1):26-33. PubMed ID: 15029258
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination.
Lennon S; Oweida A; Milner D; Phan AV; Bhatia S; Van Court B; Darragh L; Mueller AC; Raben D; Martínez-Torrecuadrada JL; Pitts TM; Somerset H; Jordan KR; Hansen KC; Williams J; Messersmith WA; Schulick RD; Owens P; Goodman KA; Karam SD
Clin Cancer Res; 2019 Jun; 25(11):3352-3365. PubMed ID: 30944125
[TBL] [Abstract][Full Text] [Related]
16. The Pyrazolo[3,4-
Neuber C; Tröster A; Löser R; Belter B; Schwalbe H; Pietzsch J
Molecules; 2020 Nov; 25(21):. PubMed ID: 33153234
[TBL] [Abstract][Full Text] [Related]
17. Fluorine-18 radiolabeling and radiopharmacological characterization of a benzodioxolylpyrimidine-based radiotracer targeting the receptor tyrosine kinase EphB4.
Mamat C; Mosch B; Neuber C; Köckerling M; Bergmann R; Pietzsch J
ChemMedChem; 2012 Nov; 7(11):1991-2003. PubMed ID: 23042640
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments.
Neuber C; Belter B; Meister S; Hofheinz F; Bergmann R; Pietzsch HJ; Pietzsch J
Molecules; 2018 Feb; 23(2):. PubMed ID: 29462967
[TBL] [Abstract][Full Text] [Related]
19. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia.
Kuang SQ; Bai H; Fang ZH; Lopez G; Yang H; Tong W; Wang ZZ; Garcia-Manero G
Blood; 2010 Mar; 115(12):2412-9. PubMed ID: 20061560
[TBL] [Abstract][Full Text] [Related]
20. Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer.
Takai N; Miyazaki T; Fujisawa K; Nasu K; Miyakawa I
Oncol Rep; 2001; 8(3):567-73. PubMed ID: 11295082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
